Literature DB >> 12124437

Temporal patterns of cytokine and apoptosis-related gene expression in spinal cords of the G93A-SOD1 mouse model of amyotrophic lateral sclerosis.

Kenneth Hensley1, Robert A Floyd, Brian Gordon, Shenyun Mou, Quentin N Pye, Charles Stewart, Melinda West, Kelly Williamson.   

Abstract

Familial amyotrophic lateral sclerosis (FALS) is often caused by gain-of-function mutations in Cu,Zn-superoxide dismutase (SOD1). Multiprobe ribonuclease protection assays (RPAs) were used to investigate expression of 36 different cytokines and apoptosis-related genes in spinal cords of mice that ubiquitously express human SOD1 bearing a glycine (r) alanine substitution at residue 93 (G93A-SOD1). Mice were studied at late presymptomatic stage (80 days), and at 120 days when the animals experience severe hindlimb paralysis and accumulation of oxidatively modified proteins. Spinal cord tissue from G93A-SOD1 mice expressed a selective subset of macrophage-typical cytokines (monokines) including interleukin (IL)1alpha, IL1beta and IL1RA at 80 days increasing by 120 days. Contrastingly, T-cell derived cytokines (lymphokines) including IL2, IL3 and IL4 were detected at low levels in non-transgenic mice but these were not elevated in G93A-SOD1 mice even at 120 days. Apoptosis-related genes were generally unaffected at 80 days but multiple caspases and death receptor components were up-regulated at 120 days; the only exceptions being FADD and the tumor necrosis factor (TNF)alpha receptor p55 which was up-regulated at 80 days and increased further at 120 days. These data indicate that in the G93A-SOD1 mouse: (i) cytokine expression changes precede bulk protein oxidation and apoptosis gene expression; (ii) lymphocyte contributions to cytokine expression in FALS are likely minor; and (iii) TNFalpha and its receptors may link inflammation to apoptosis in ALS.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12124437     DOI: 10.1046/j.1471-4159.2002.00968.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  57 in total

1.  Cardiovascular disease and diagnosis of amyotrophic lateral sclerosis: A population based study.

Authors:  Marianthi-Anna Kioumourtzoglou; Ryan M Seals; Ole Gredal; Murray A Mittleman; Johnni Hansen; Marc G Weisskopf
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2016-07-20       Impact factor: 4.092

Review 2.  Targeting TNF-α to elucidate and ameliorate neuroinflammation in neurodegenerative diseases.

Authors:  Kathryn A Frankola; Nigel H Greig; Weiming Luo; David Tweedie
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-05       Impact factor: 4.388

Review 3.  [Amyotrophic lateral sclerosis. Current clinical trials and underlying pathomechanisms].

Authors:  K Kollewe; R Dengler; S Petri
Journal:  Nervenarzt       Date:  2008-06       Impact factor: 1.214

Review 4.  Stem cell-derived motor neurons: applications and challenges in amyotrophic lateral sclerosis.

Authors:  Jason R Thonhoff; Luis Ojeda; Ping Wu
Journal:  Curr Stem Cell Res Ther       Date:  2009-09       Impact factor: 3.828

Review 5.  Inflammation in ALS and SMA: sorting out the good from the evil.

Authors:  Dimitra Papadimitriou; Virginia Le Verche; Arnaud Jacquier; Burcin Ikiz; Serge Przedborski; Diane B Re
Journal:  Neurobiol Dis       Date:  2009-10-13       Impact factor: 5.996

Review 6.  T cell-microglial dialogue in Parkinson's disease and amyotrophic lateral sclerosis: are we listening?

Authors:  Stanley H Appel; David R Beers; Jenny S Henkel
Journal:  Trends Immunol       Date:  2009-10-31       Impact factor: 16.687

Review 7.  Use of biomarkers in ALS drug development and clinical trials.

Authors:  Nadine Bakkar; Ashley Boehringer; Robert Bowser
Journal:  Brain Res       Date:  2014-10-24       Impact factor: 3.252

Review 8.  Antioxidants in central nervous system diseases: preclinical promise and translational challenges.

Authors:  Chandrashekhar D Kamat; Sunyana Gadal; Molina Mhatre; Kelly S Williamson; Quentin N Pye; Kenneth Hensley
Journal:  J Alzheimers Dis       Date:  2008-11       Impact factor: 4.472

9.  Reduction of circulating endothelial cells in peripheral blood of ALS patients.

Authors:  Svitlana Garbuzova-Davis; Robert L Woods; Michael K Louis; Theresa A Zesiewicz; Nicole Kuzmin-Nichols; Kelly L Sullivan; Amber M Miller; Diana G Hernandez-Ontiveros; Paul R Sanberg
Journal:  PLoS One       Date:  2010-05-12       Impact factor: 3.240

10.  Progressive changes in microglia and macrophages in spinal cord and peripheral nerve in the transgenic rat model of amyotrophic lateral sclerosis.

Authors:  David J Graber; William F Hickey; Brent T Harris
Journal:  J Neuroinflammation       Date:  2010-01-28       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.